SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 30, 2006--Hana Biosciences (NASDAQ:HNAB - News), a biopharmaceutical company focused on advancing cancer care, announced that Phase I trials in solid tumors and non small cell lung cancer (NSCLC) with Talotrexin (PT-523) will be presented at the upcoming 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia. Details on the presentations are as follows:
